These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 34769131)

  • 21. SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation.
    Almeida LO; Neto MPC; Sousa LO; Tannous MA; Curti C; Leopoldino AM
    Oncotarget; 2017 Apr; 8(16):26802-26818. PubMed ID: 28460463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone Modifications in Aging: The Underlying Mechanisms and Implications.
    Wang Y; Yuan Q; Xie L
    Curr Stem Cell Res Ther; 2018; 13(2):125-135. PubMed ID: 28820059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2008 Oct; 68(1):29-36. PubMed ID: 18424067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The promise and failures of epigenetic therapies for cancer treatment.
    Bojang P; Ramos KS
    Cancer Treat Rev; 2014 Feb; 40(1):153-69. PubMed ID: 23831234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of novel epigenetic molecular-targeting agents].
    Sowa Y; Sakai T
    Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiling of epigenetic chromatin modification enzymes and histone marks by cigarette smoke: implications for COPD and lung cancer.
    Sundar IK; Rahman I
    Am J Physiol Lung Cell Mol Physiol; 2016 Dec; 311(6):L1245-L1258. PubMed ID: 27793800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
    Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
    PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
    Carter CA; Zeman K; Day RM; Richard P; Oronsky A; Oronsky N; Lybeck M; Scicinski J; Oronsky B
    Oncotarget; 2016 Jun; 7(26):40781-40791. PubMed ID: 27007055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
    Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
    Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
    Vendetti FP; Rudin CM
    Expert Opin Biol Ther; 2013 Sep; 13(9):1273-85. PubMed ID: 23859704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetically maintained SW13+ and SW13- subtypes have different oncogenic potential and convert with HDAC1 inhibition.
    Davis MR; Daggett JJ; Pascual AS; Lam JM; Leyva KJ; Cooper KE; Hull EE
    BMC Cancer; 2016 May; 16():316. PubMed ID: 27188282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
    Leng X; Wang J; An N; Wang X; Sun Y; Chen Z
    Oncogene; 2020 Oct; 39(41):6468-6479. PubMed ID: 32879445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer.
    Luo H; Shan J; Zhang H; Song G; Li Q; Xu CX
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):960-970. PubMed ID: 35189321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic landscape of amphetamine and methamphetamine addiction in rodents.
    Godino A; Jayanthi S; Cadet JL
    Epigenetics; 2015; 10(7):574-80. PubMed ID: 26023847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
    Bezecny P
    Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.
    Seol HS; Akiyama Y; Shimada S; Lee HJ; Kim TI; Chun SM; Singh SR; Jang SJ
    Cancer Lett; 2014 Oct; 353(2):232-41. PubMed ID: 25063738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The natural tumor suppressor protein maspin and potential application in non small cell lung cancer.
    Lonardo F; Li X; Kaplun A; Soubani A; Sethi S; Gadgeel S; Sheng S
    Curr Pharm Des; 2010 Jun; 16(16):1877-81. PubMed ID: 20337574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.